Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial

医学 超重 队列 安慰剂 腰围 肥胖 减肥 不利影响 重量变化 内科学 病理 替代医学
作者
Shobha Bhattachar,Lai San Tham,Li Yan,Laiyi Chua,S. Ng,Yuanyuan Tang,Hilda Ibriga,Wei Ni,Sirel Gurbuz,Kieren J. Mather,Melissa K. Thomas
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:27 (11): 6460-6469 被引量:14
标识
DOI:10.1111/dom.70040
摘要

AIM: Mazdutide, an agonist of glucagon-like peptide-1 and glucagon receptors, significantly reduced weight in early phase trials at doses up to 10 mg. This randomized, double-blind, placebo-controlled Phase 1 trial evaluated the safety and efficacy of mazdutide up to 16 mg in adults with overweight or obesity. MATERIALS AND METHODS: Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous injections of mazdutide (n = 24) or placebo (n = 8) for 20 weeks. Two mazdutide dose escalation regimens (Cohorts 1 and 2, n = 12 each) were used to reach a 16-mg target dose. Data were analysed using descriptive statistics and mixed model repeated measures to estimate least square means with standard error (SE). RESULTS: At Week 20, mean percent change from baseline in body weight was -20.0% (SE: 1.9) for Cohort 1 and -21.0% (1.2) for Cohort 2 versus -0.1% (1.5) for placebo (p < 0.001). Weight loss of ≥15% was achieved by 66.7% of Cohort 1 and 75.0% of Cohort 2. No placebo participants achieved ≥5% weight loss. Mean percent change in waist circumference was -12.0% (SE: 1.7) in Cohort 1 and -17.0% (1.7) in Cohort 2 versus -0.8% (2.1) in placebo (p < 0.001). Improved fasting metabolic biomarker profiles and reduced appetite were associated with mazdutide treatment. No serious adverse events (AEs) were reported, and the most common AEs were mild or moderate gastrointestinal disorders. CONCLUSIONS: Mazdutide at 16 mg was well tolerated and associated with greater weight loss at higher doses than previously studied and improved metabolic regulation in adults with overweight or obesity. US Clinical Trials Registry: NCT05623839.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
joule完成签到,获得积分10
1秒前
江江完成签到,获得积分10
2秒前
2秒前
2秒前
Ava的应助被dyq采纳,获得10
3秒前
成就煎饼发布了新的文献求助10
3秒前
qys发布了新的文献求助10
3秒前
3秒前
4秒前
5秒前
MSY完成签到 ,获得积分10
5秒前
小二郎的应助被干饭啦采纳,获得10
5秒前
奶茶电竞精神完成签到 ,获得积分10
5秒前
空白发布了新的文献求助30
6秒前
大个的应助被叶素绿采纳,获得10
7秒前
7秒前
余香的应助被jzt12138采纳,获得10
8秒前
木子发布了新的文献求助10
9秒前
9秒前
GFY发布了新的文献求助10
9秒前
9秒前
fanfan发布了新的文献求助10
10秒前
华仔的应助被谨慎的秋烟采纳,获得10
10秒前
12秒前
zaka完成签到,获得积分20
13秒前
sun完成签到,获得积分10
14秒前
14秒前
小朋友发布了新的文献求助10
15秒前
大橙子发布了新的文献求助10
15秒前
leajay完成签到,获得积分20
15秒前
orixero的应助被h11采纳,获得10
15秒前
Rio完成签到,获得积分10
16秒前
英姑的应助被风中的宛白采纳,获得10
16秒前
16秒前
行之完成签到 ,获得积分10
17秒前
17秒前
17秒前
无极微光的应助被里予采纳,获得20
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163746
求助须知:如何正确求助?哪些是违规求助? 9557874
关于积分的说明 21742203
捐赠科研通 7754407
什么是DOI,文献DOI怎么找? 3428345
关于科研通互助平台的介绍 2553000
邀请新用户注册赠送积分活动 2472945